How to Quit Smoking: Effective Medications and Behavioral Support

Author: Angela Bogdanova · Published: October 19, 2026 · Editorial Policy

Research cluster: Substance Use Disorders and Addiction Recovery · Written by Artificial Sapiens

Quitting smoking is most effective when it is treated as a structured health intervention: choose an evidence-based medication when appropriate, pair it with behavioral support, anticipate nicotine withdrawal, and maintain follow-up through the period when urges and learned smoking routines are strongest. For many nonpregnant adults who smoke cigarettes, varenicline or a combination of a nicotine patch with a faster-acting nicotine replacement product provides an effective pharmacological starting point; bupropion and other context-dependent options also have an established role. Counseling, telephone quitlines, and accessible digital support increase the practical capacity to initiate and sustain abstinence. The World Health Organization (WHO) recommends effective pharmacotherapy and behavioral care together, while the Centers for Disease Control and Prevention (CDC) emphasizes that using counseling and medication together gives smokers their best chance of quitting. WHO, 2024 CDC, 2024

A smoking cessation plan works by addressing two processes at once. Medication can reduce the physiological discomfort of nicotine withdrawal and, for some agents, the reinforcing experience of smoking. Behavioral treatment examines the circumstances in which cigarettes have become linked to waking, meals, driving, work breaks, stress, social contact, and emotional regulation. Follow-up allows the plan to be adjusted as clinical symptoms and real-life obstacles emerge. Success is measured through sustained reductions in combustible cigarette exposure and, when the goal is complete cessation, appropriately defined and preferably verified abstinence—not through one isolated day without smoking.

This article examines how to quit combustible cigarettes using treatments with clinical evidence. Diagnostic classification of nicotine dependence and tobacco use disorder belongs to the broader clinical science of substance use disorders, while the central question here is practical: which cessation treatments help, how to choose among them, what to expect after stopping, and how to sustain the change safely.

Why quitting smoking changes health outcomes

Combustible tobacco smoke exposes the respiratory and cardiovascular systems to carbon monoxide, fine particles, oxidants, carcinogens, and thousands of other constituents. Nicotine is central to tobacco dependence, yet much of the mortality and organ damage from cigarette smoking comes from the products of combustion. This distinction explains why medicinal nicotine replacement can be substantially safer than continuing to smoke even though it still delivers nicotine. Stopping smoking reduces cardiovascular, respiratory, cancer, reproductive, and overall mortality risks. Benefits occur at every adult age, including for people who have smoked for decades and those already living with coronary heart disease or chronic obstructive pulmonary disease. CDC, Benefits of Quitting Smoking FDA, 2026

The benefits accumulate across different time scales. Some physiological changes begin within hours or days; respiratory symptoms commonly improve over months; risks of heart attack, stroke, lung cancer, and other smoking-related disease diminish over years. An individual should not interpret a persistent cough, breathlessness, or difficulty exercising as evidence that quitting has failed. A clinician can evaluate symptoms and screen for smoking-related disease when indicated. Quitting does not reverse every preexisting injury, but it changes future exposure and risk in a clinically meaningful direction. CDC, 2024

What makes stopping cigarettes difficult?

Cigarettes produce rapidly repeated nicotine delivery, and the sensory sequence of handling, lighting, inhaling, and taking breaks becomes tightly learned. Nicotine activates nicotinic acetylcholine receptors in reward-related and other neural circuits, participating in reinforcement, attention, and adaptation to repeated exposure. Over time, the absence of nicotine can produce craving, irritability, anxiety, restlessness, difficulty concentrating, altered sleep, and changes in appetite. Smoking may then be experienced as rapid relief from withdrawal. These processes interact with stress, availability, social environment, expectations, and conditioned cues. Treating both pharmacology and routines is therefore more coherent than relying on motivation alone. WHO, 2024 CDC, Withdrawal Symptoms

A craving is an urge to smoke, not a diagnostic verdict and not an instruction that must be acted upon. Physical dependence describes adaptation to nicotine exposure; tolerance describes diminished response with repeated exposure; withdrawal names symptoms after reducing exposure. Tobacco use disorder is a clinical diagnosis based on a broader pattern of impaired control and impairment. These concepts are related, but they serve different purposes during cessation counseling. A person can benefit from smoking cessation treatment without first accepting a particular identity or label.

Repeated previous attempts are clinically useful information. They can reveal whether the principal difficulty was strong morning withdrawal, stress-triggered smoking, inadequate medication coverage, adverse effects, insufficient follow-up, social exposure, cost, or a return to cigarettes after a period of abstinence. Each observation can inform a more appropriate next attempt.

The evidence-based foundation: medications plus behavioral treatment

Large bodies of randomized trial evidence support nicotine replacement therapy (NRT), varenicline, and bupropion for smoking cessation in adults. A WHO guideline additionally recommends cytisine where it is legally available and clinically appropriate. The American Thoracic Society (ATS) recommends varenicline over either a nicotine patch or bupropion when initiating treatment for tobacco-dependent adults, while recognizing individual contraindications, preferences, and access barriers. Combined patch-plus-short-acting NRT is more effective than using one NRT formulation alone. WHO, 2024 ATS, 2020 Cochrane NRT Review, 2023

Medication and counseling work through partially different pathways, so combining them is an evidence-based first-line strategy. A Cochrane review encompassing 52 pooled trials with 19,488 participants found that combined pharmacotherapy and behavioral treatment improved cessation at six months or later relative to minimal intervention or usual care (risk ratio 1.83, 95% confidence interval 1.68–1.98). The result is a comparative effect across research settings, not a promise that any particular patient will quit. Counseling can be delivered by an individual clinician, a group program, a trained quitline counselor, or a supported remote service. Stead et al., 2016

Treatment selection should consider previous response, current smoking pattern, coexisting illnesses, pregnancy possibility, other medications, prior adverse reactions, personal priorities, and practical access. A clinician or pharmacist can review contraindications and help construct a regimen. This article explains treatment classes and decisions rather than providing an unsupervised medication schedule.

Varenicline: a highly effective prescription option

Varenicline is a partial agonist at neuronal alpha4beta2 nicotinic acetylcholine receptors. It can reduce craving and withdrawal while also reducing some of the satisfaction associated with smoking. Trials consistently establish its efficacy over placebo. A Cochrane review involving 75 trials and 45,049 participants found high-certainty evidence that varenicline improved sustained cessation versus placebo (relative risk 2.32, 95% confidence interval 2.15–2.51), and higher quit rates than either bupropion or single-form NRT. It found no clear difference compared with combination NRT in a smaller and less certain set of direct comparisons. Livingstone-Banks et al., 2023

Nausea is the most common unwanted effect; disturbed sleep and unusual dreams are also reported. A prescribing clinician should assess kidney function when relevant, review possible side effects, and discuss changes in mood or behavior. Randomized evidence in adults with psychiatric conditions supports using varenicline when appropriate rather than automatically withholding it because of a psychiatric diagnosis. Clinical monitoring remains important when substantial depression, bipolar disorder, psychosis, suicidality, or concurrent drug use is present. ATS, 2020 Cochrane, 2023

Treatment commonly begins before the planned cigarette-free date, and a clinician may consider extended treatment for someone who benefits but remains at high risk of returning to smoking. ATS supports longer controller treatment beyond standard short courses for suitable adults; medication duration is individualized. Persistent nausea, severe mood changes, unusual behavior, or other concerning symptoms merit timely professional review. New suicidal thoughts or an immediate danger to oneself call for urgent emergency evaluation. ATS, 2020

Nicotine replacement therapy: steady coverage and help for breakthrough cravings

NRT provides nicotine through medicinal products without the toxic combustion mixture generated by cigarettes. Available forms differ by delivery pattern and local regulation. A transdermal patch delivers nicotine gradually across the day; gum and lozenges are oral options that can respond to episodes of craving. In the United States, nicotine inhalers and nasal sprays are prescription products. Pharmacists and clinicians can help select a formulation that fits work routines, swallowing difficulties, oral conditions, skin sensitivity, and personal preference. CDC, 2024

Combining a nicotine patch with a short-acting product addresses baseline withdrawal and breakthrough urges. A 2023 Cochrane review found high-certainty evidence that combination NRT improved six-month or longer abstinence over a single NRT type. In clinical use, consistent treatment matters: some people stop using NRT when a craving disappears, only to experience withdrawal later in the day, while others use an oral product ineffectively or discontinue it because of correctable irritation. A clinician or pharmacist can review product technique, fit, and adherence without requiring the person to withstand preventable discomfort. Theodoulou et al., 2023

Adverse effects depend on formulation. Patches may irritate the skin or disrupt sleep; oral preparations can cause mouth or throat irritation and gastrointestinal symptoms. If a nicotine product causes palpitations, substantial dizziness, vomiting, or other pronounced symptoms, prompt medical review is appropriate. People with recent serious cardiac events, pregnancy, complex illness, or multiple medications should discuss treatment choice with a clinician. For an adult who smokes, the health risks of continuing combustible smoking are substantially greater than those of appropriately used cessation NRT. CDC, Quit Medicines and Safety

Bupropion: an established non-nicotine medication

Bupropion sustained release is a prescription medicine with antidepressant activity that also increases smoking abstinence. Its pharmacological effects include modulation of norepinephrine and dopamine signaling. It can be useful when a person prefers a non-nicotine medicine, has previously benefited from it, or has other clinical circumstances supporting its selection. Its average smoking-cessation efficacy is lower than varenicline in comparative trials, while still exceeding placebo outcomes. Cochrane, 2023 WHO, 2024

Bupropion requires careful screening for seizure risk, including seizure disorder, current or previous bulimia or anorexia nervosa, and abrupt withdrawal from alcohol, benzodiazepines, barbiturates, or certain antiepileptic drugs. Monoamine oxidase inhibitors and some other medications create important contraindications or interactions. Insomnia, dry mouth, and agitation can occur. People with bipolar disorder or major mood symptoms need individualized psychiatric review. A prescriber should assess the complete medication and medical history rather than extrapolating from a family member's successful experience. DailyMed, bupropion SR

Bupropion is sometimes paired with NRT or other treatment under professional guidance. WHO considers certain combinations when first-line options have produced an inadequate response, with evidence quality varying by pairing. More medication does not automatically mean a better choice, particularly when adverse effects or drug interactions are relevant. WHO, 2024

Cytisine: an effective option with country-specific availability

Cytisine (also called cytisinicline in some development contexts) is another nicotinic receptor partial agonist. WHO recommends it as an evidence-supported cessation treatment, while noting that regulatory approvals, supply, and prescribing arrangements differ considerably across countries. Cochrane found moderate-certainty evidence that cytisine improves quitting versus placebo and that direct evidence comparing it with varenicline remains limited. It should therefore be discussed in relation to its specific licensed product and national practice requirements. A medicine approved in one health system should not be presumed licensed or available in another. WHO, 2024 Livingstone-Banks et al., 2023

Which medication is most effective, and what does that mean?

Comparative effectiveness is a probability estimated from groups of participants over defined follow-up periods. WHO and ATS give particular weight to varenicline and combination NRT. In the Cochrane partial-agonist review, varenicline exceeded bupropion and single-form NRT, while the comparison with combination NRT remained less certain. A broader 2023 component network meta-analysis placed varenicline, cytisine, and nicotine e-cigarettes among the more effective investigated interventions, and also identified strong efficacy for combination NRT. Such rankings are sensitive to differences in trials, comparisons, confidence intervals, and availability; they do not establish the best plan for an individual with contraindications or complex needs. WHO, 2024 Cochrane network meta-analysis, 2023

Absolute quit probabilities depend strongly on the population studied, baseline support, medication access, adherence, and the definition of abstinence. A person should interpret a relative risk of two as approximately doubling the chance of an outcome compared with the specified comparison group, rather than guaranteeing that half of all treated smokers will quit. Clinically meaningful decisions also include tolerability, interactions, cost, availability, previous attempts, and whether the chosen treatment can be used consistently.

Behavioral support: how counseling changes the quit attempt

Effective smoking cessation counseling is specific and collaborative. It identifies triggers, anticipates predictable obstacles, teaches responses to craving, addresses mood and routine changes, and arranges continued contact. It may incorporate motivational interviewing, problem solving, goal setting, functional analysis of smoking episodes, coping skills, and support from people in the smoker's environment. For someone unsure about quitting, counseling can clarify priorities and ambivalence without making abstinence a prerequisite for receiving help. WHO, 2024 USPSTF, 2021

An evidence review of individual behavioral counseling found higher long-term cessation rates than minimal contact when medication was not routinely supplied. Telephone counseling has moderate-certainty evidence of benefit in both people who called quitlines themselves and those proactively offered calls. This evidence supports multiple delivery formats, especially when work, childcare, disability, transport, or local service availability make regular in-person visits difficult. Lancaster and Stead, 2017 Cochrane Telephone Counseling Review

Brief advice by a clinician is also useful: it makes smoking status visible within ordinary health care, communicates the available treatments, and can lead directly to an offer of medication and a counseling referral. WHO recommends routinely offering brief counseling in health-care settings and more intensive face-to-face, group, or telephone support to interested adults. WHO, 2024

A practical smoking cessation plan

Establish a baseline and choose a workable goal

A useful first conversation establishes the number of cigarettes smoked, timing of the first cigarette, routine triggers, previous quit attempts, time spent in smoke-free environments, and symptoms during periods without nicotine. It also asks about pregnancy possibility, heart disease, kidney disease, seizure risk, psychiatric conditions, alcohol or sedative withdrawal, current medications, and concerns about affordability or access. These details guide medication and safety decisions. A smoking history is a clinical assessment, not a test of character.

A person may select a target quit date and organize treatment around it. Some evidence-based medication strategies begin before the quit date; others can be arranged around an immediate attempt. Someone who is not ready to stop abruptly can still discuss a treatment-assisted pathway and planned reduction of smoking exposure with a clinician. ATS specifically supports offering varenicline treatment to adults who are not yet prepared for immediate abstinence rather than withholding all pharmacotherapy until readiness is declared. ATS, 2020

Make the smoking environment easier to navigate

A plan identifies the situations most likely to trigger smoking and assigns a realistic alternative response to each. For an individual who smokes with morning coffee, the alternative may involve changing location or the sequence of the morning routine. For someone who associates smoking with driving, it may mean removing smoking equipment from the car, preparing an alternative for breaks, and planning nicotine medication coverage with a clinician. For social triggers, it may involve communicating the quit plan and temporarily adjusting when and where breaks occur.

Removing cigarettes, lighters, and ashtrays is useful as an environmental adjustment, but it does not substitute for withdrawal treatment or social support. The goal is to reduce automatic exposure to cues and increase the availability of a different action at the moment an urge arises.

Arrange medication and counseling together

A qualified clinician or pharmacist can explain the available medication options, assess contraindications, review other prescriptions, and establish how to recognize and report adverse effects. Arrange quitline or counseling contact before or around the stop date, including follow-up in the early period of withdrawal. The CDC directs people in the United States to 1-800-QUIT-NOW, a free confidential route to state quitline coaching, while Smokefree.gov offers additional federal resources. Access outside the United States depends on local health systems and national quitlines. CDC, 2024

Track meaningful outcomes without turning slips into labels

A useful record can track smoke-free days, cigarette exposure, craving intensity, medication use, adverse effects, and triggers that preceded smoking. The purpose is to decide whether the plan needs adjusting. A single cigarette after a period of abstinence is a lapse or return to use that warrants immediate attention to triggers and follow-up; it does not require abandoning the overall treatment goal. Repeated smoking or a sustained return may require reassessment of medication, counseling intensity, environmental stressors, or co-occurring symptoms.

Nicotine withdrawal: what to expect and when to seek help

Withdrawal commonly involves irritability, anxiety, depressed mood, restlessness, increased appetite, difficulty concentrating, sleep disturbance, and intense urges to smoke. Symptoms tend to be most prominent in the first days and weeks and gradually recede for many people, although conditioned cravings can recur much later. Their course varies with smoking intensity, previous dependence, stress, sleep, and treatment use. Medication can reduce the burden of withdrawal, while behavioral strategies help manage triggers that remain after acute symptoms subside. CDC, Withdrawal Symptoms

For a brief craving episode, useful responses can include delaying action until the urge changes, taking a short walk, practicing slow breathing, contacting a supportive person, changing the immediate setting, or using a prescribed or pharmacist-recommended short-acting NRT product as instructed. These strategies are not equally effective for everyone; they are options to test as part of a planned response. Poor sleep may improve with regular waking hours and attention to caffeine intake. Appetite changes can be met with regular meals and feasible activity rather than an additional restrictive diet that creates avoidable stress during quitting.

Nicotine withdrawal itself is generally uncomfortable rather than the type of potentially life-threatening withdrawal seen with heavy alcohol or benzodiazepine dependence. Severe chest pain, major shortness of breath, fainting, sudden neurologic symptoms, or acute confusion require urgent medical assessment irrespective of whether they occur during a quit attempt. Suicidal thoughts, psychosis, or rapidly escalating mood symptoms also warrant urgent professional help; an immediate danger requires emergency services. People concurrently stopping alcohol or benzodiazepines after sustained use need medical evaluation because those withdrawal syndromes can produce seizures and other emergencies.

Stress, anxiety, mood, and the perception that smoking helps

Many people experience cigarettes as a way to regulate stress. Part of the short-lived relief may reflect reversal of nicotine withdrawal between cigarettes rather than improvement of the stressor itself. External pressures, depression, trauma exposure, unstable housing, and social isolation can make changing routines more difficult, so the treatment plan should address the real circumstances instead of attributing every barrier to poor motivation. Counseling may focus on coping skills, social resources, accessible treatment, and referral for co-occurring mental health needs.

Anxiety and sleep disruption after quitting should be assessed in context. They may reflect transient withdrawal, a preexisting anxiety condition, a change in caffeine exposure, another medication effect, or a combination of these. A clinician can help distinguish them, especially when symptoms are severe or persistent. Smoking cessation treatment can be coordinated with psychiatric care rather than deferred indefinitely until all psychological symptoms disappear. ATS, 2020

How long should a person use cessation treatment?

Medication courses and behavioral follow-up can extend beyond the earliest nicotine withdrawal period. A 2020 ATS guideline recommends controller treatment lasting longer than twelve weeks over a shorter standard course for suitable tobacco-dependent adults, based on moderate-certainty evidence. A Cochrane relapse-prevention review found evidence supporting extended varenicline treatment among people who had achieved abstinence, while evidence for extending bupropion or NRT specifically to prevent relapse was less compelling or more uncertain. Duration must follow the specific agent's labeling and clinician judgment rather than a universal calendar for every smoker. ATS, 2020 Livingstone-Banks et al., 2019

Regular review is valuable even when a patient reports complete abstinence. It checks medication side effects, new triggers, changes in employment or housing, emerging depression, and future high-risk situations. Follow-up may involve a primary care clinician, pharmacist, quitline, community program, or behavioral health professional. A person who stopped using medication prematurely because of cost or nausea may benefit from a different option or assistance with access.

What if someone smokes again after quitting?

A return to smoking is information about the current treatment plan. A rapid reassessment identifies what preceded the episode, whether withdrawal remained uncontrolled, whether medication was stopped, and whether a specific stressor or social setting was involved. Continuing contact and promptly re-engaging with evidence-based treatment can preserve gains in knowledge, skills, and confidence. The public health endpoint remains sustained reduction of exposure to combustible smoke, with complete abstinence as the central goal of most cessation trials.

Relapse-prevention interventions should be represented accurately. The Cochrane review did not find consistent evidence that stand-alone behavioral relapse-prevention programs added after successful quitting further improved outcomes across studied groups, while extended pharmacological treatment with varenicline showed more encouraging results. This does not invalidate counseling as an effective cessation treatment at initiation; it distinguishes research questions about starting abstinence from those about maintaining it after a successful quit. Livingstone-Banks et al., 2019

Electronic cigarettes and smoking cessation: efficacy, regulation, and uncertainty

Nicotine-containing electronic cigarettes warrant a distinct evidence assessment. The 2026 Cochrane living systematic review, with evidence current to January 1, 2026, concluded with high certainty that nicotine e-cigarettes help more adults stop smoking combustible cigarettes than conventional NRT in the randomized trials studied. The review reported no detected serious short-term safety signal compared with NRT but emphasized that longer and larger trials are needed to evaluate long-term safety. Trial products, patterns of use, and regulatory environments vary; evidence from regulated research products cannot automatically be applied to every marketed or illicit device. Lindson et al., 2026

Smoking cessation efficacy, continuing nicotine exposure, long-term inhalation risk, and population-level youth initiation are different outcomes. In the United States, an FDA marketing authorization for an electronic tobacco product is not approval of that product as a smoking cessation medicine or a declaration that it is safe. FDA's current authorized-product list explicitly distinguishes lawful marketing from safety or therapeutic approval. This regulatory distinction is especially important when a product is promoted using a clinical study that addressed quitting cigarettes rather than long-term disease outcomes. FDA, Authorized E-Cigarettes

For adults who are interested in quitting, approved cessation medicines and counseling remain a clear evidence-based clinical pathway. An adult who currently uses e-cigarettes to displace cigarettes can discuss complete replacement of combustible smoking, ongoing nicotine use, eventual nicotine cessation goals, and product safety with a clinician. Dual long-term use of cigarettes and vaping does not deliver the same elimination of combustion exposure as completely stopping cigarettes. Adolescents and people who do not currently use nicotine should not initiate nicotine vaping as a health intervention. Decisions during pregnancy need separate clinical evaluation because of fetal nicotine exposure and limited treatment-specific evidence. WHO, 2024 USPSTF, 2021

Digital interventions, text messages, and AI systems

Text-message cessation programs can extend contact between clinical visits and provide timely reminders, coping prompts, and links to evidence-based services. A Cochrane review found moderate-certainty evidence that automated text messages improve long-term abstinence compared with minimal support and may add benefit when combined with other interventions. The same review rated evidence on smartphone apps much less certain. WHO supports digital tools as adjuncts or self-management resources, while preserving access to evidence-based medication and human clinical care. Whittaker et al., 2019 WHO, 2024

A general AI chatbot, a conversational companion, a clinically evaluated digital therapeutic, and a regulated medical device represent different intervention categories. A chatbot that offers encouragement has not thereby demonstrated sustained smoking abstinence, safe medication guidance, privacy protection, or appropriate response to suicidality. Research claims should be linked to the exact product, trial design, population, outcome, and safety surveillance. Digital systems may increase access to education and reminders, but clinical medication selection, psychiatric emergencies, pregnancy-related decisions, and complex drug interactions call for qualified professionals. Evidence of user engagement or emotional attachment is not evidence of therapeutic effectiveness.

Smoking cessation during pregnancy and postpartum

Stopping combustible smoking before pregnancy or during pregnancy improves maternal and infant health, and quitting at any stage can be beneficial. The USPSTF recommends behavioral counseling for pregnant people who use tobacco. It finds the evidence insufficient to determine the balance of benefits and harms of pharmacotherapy for cessation during pregnancy, reflecting limited and heterogeneous pregnancy-specific trials. The evidence is also insufficient for e-cigarettes as a pregnancy cessation intervention. These are evidence judgments, and clinical care must account for both smoking-related harm and the uncertainties of particular treatments. USPSTF, 2021

Pregnancy cessation plans should be coordinated with obstetric care, using respectful counseling, assessment of smoking intensity, and support that continues after birth. Where smoking persists despite counseling, a clinician can discuss individualized options and the uncertainty of medication evidence rather than recommending self-directed use or abrupt changes to prescribed treatment. The postpartum period brings sleep disruption, social demands, and recurrent exposure to smoking in some households, so sustained follow-up and smoke-free environments matter for the parent and child. CDC, Benefits of Quitting

Adolescents and young adults

Nicotine exposure during adolescence raises developmental and addiction-related concerns. Treatment for adolescents must be tailored to developmental stage, confidentiality, family context, school environment, comorbidity, and product type. The strong adult pharmacotherapy evidence cannot automatically be transferred to minors; the FDA notes that currently approved NRT products are approved for adult cessation, and clinicians should assess youth treatment individually. Behavioral engagement, protection from tobacco and nicotine marketing, and developmentally suitable support are central. FDA, Nicotine and Tobacco Addiction

Young adults may have intermittent or social patterns of smoking, high exposure to nicotine vaping, and unstable transitions in education or employment. Lower daily cigarette counts do not mean harmless exposure or eliminate the value of support. The plan should identify which products are being used, whether combustible cigarettes remain part of the pattern, and what outcome—ending cigarette use, nicotine use, or both—is intended.

Mental illness, substance use, and individualized support

Depression, anxiety, bipolar disorder, schizophrenia, and other substance use conditions can coexist with smoking and may affect medication choices and follow-up. The ATS guideline recommends varenicline over a nicotine patch when suitable in adults with psychiatric comorbidity, based on evidence that includes randomized clinical trials. Treatment teams should still review mental state, suicidal risk, prescribed psychotropics, and the possibility that mood symptoms during cessation overlap with withdrawal or an underlying disorder. ATS, 2020

Smoking cessation can also change the metabolism of some medicines because compounds in tobacco smoke induce certain hepatic enzymes. When smoking stops, serum concentrations of affected drugs may change; examples relevant to psychiatric care include clozapine and olanzapine. This is a property of tobacco smoke exposure rather than medicinal nicotine itself. People taking medications with clinically significant smoking-related interactions should tell their prescriber about substantial smoking reduction or cessation so monitoring and prescribing can be adjusted. The same principle applies to relevant nonpsychiatric medicines. Treatment coordination is especially important when alcohol use, benzodiazepines, or other substances introduce separate withdrawal or interaction risks.

People with heart disease, lung disease, or hospitalization

A diagnosis of coronary heart disease, chronic obstructive pulmonary disease, or cancer can increase the potential gains from avoiding combustible tobacco. It may also create a timely opportunity to offer medication and counseling as part of ongoing medical care. The CDC identifies reduced cardiovascular disease and mortality, less respiratory symptom burden, and slower decline of lung function among benefits after quitting. Clinical choice of NRT or prescription medications should be individualized when the person has unstable cardiac symptoms, recent major events, or complex comorbidity. CDC, Benefits of Quitting

Hospitals can initiate cessation treatment and connect it to care after discharge. A Cochrane systematic review found that sustained counseling and pharmacotherapy beyond discharge improved cessation compared with hospital-only counseling, highlighting the importance of continuity. Withdrawal management during an admission is a starting point, while an effective discharge plan provides the means to continue avoiding cigarettes in ordinary life. Cochrane, Hospital-Initiated Interventions

Access, equity, and real-world effectiveness

Clinical efficacy in a randomized trial does not guarantee equally accessible care in every setting. Medication cost, coverage, supply interruptions, language, work schedules, rural distance, disability accommodations, caregiving, housing insecurity, and distrust arising from previous health-care experiences can all affect whether treatment is available and sustained. WHO supports accessible cessation services through health systems and community delivery channels. A clinician or health program can reduce barriers by offering multiple treatment modalities, culturally appropriate counseling, clear referrals, and practical continuity rather than relying on repeated brief warnings about smoking. WHO, 2024

Programs should evaluate treatment uptake and reach alongside abstinence. When follow-up is limited to people who remain engaged, apparent success rates may overestimate effectiveness in the larger population. Likewise, a program that reports large numbers of registered users without assessing cigarette abstinence demonstrates engagement, not proven cessation. Patients and decision-makers benefit from transparent outcome definitions, actual follow-up time, attrition, and whether abstinence was self-reported or biochemically verified.

How to evaluate the strength of the research

Established findings include the efficacy of varenicline, NRT, bupropion, combination NRT, individual and telephone behavioral support, and treatment combining medication with counseling. Cytisine is supported by randomized evidence but is subject to country-specific regulatory availability and somewhat less certain comparative evidence. These conclusions derive from large reviews and formal clinical guidelines rather than a single small study. WHO, 2024 Cochrane, 2023

Evidence on nicotine e-cigarettes as a cigarette cessation tool now includes a 2026 high-certainty Cochrane conclusion for quitting combustible cigarettes relative to NRT in studied populations. Long-term vaping safety, clinical regulatory status, effects of product innovation, and population-wide consequences remain separate and less settled questions. Evidence for particular commercial apps and unvalidated AI conversations is limited and cannot be inferred from the text-message literature. Behavioral interventions developed expressly for relapse prevention after successful abstinence have shown inconsistent additional benefit; extended varenicline has more supportive research for selected patients. Lindson et al., 2026 Livingstone-Banks et al., 2019

Strong inference requires attention to randomized allocation, adherence, loss to follow-up, biochemical validation, baseline smoking intensity, psychiatric and medical comorbidity, and the exact follow-up outcome. Relative risk describes a comparison between specified groups. A six-month point-prevalence estimate and twelve-month continuous abstinence are not interchangeable. Trials of nicotine vaping may show smoking abstinence while reporting continued use of nicotine-containing products; this distinction is fundamental for interpreting health outcomes.

Frequently Asked Questions

What is the best way to quit smoking?

For many nonpregnant adults, the best-supported approach is an appropriately selected cessation medication combined with behavioral counseling or quitline support. Varenicline and combination nicotine replacement are especially effective options, while bupropion and cytisine can be appropriate in certain clinical and regulatory contexts. Selection should consider contraindications, access, and prior response. WHO, 2024

Can I quit smoking without medication?

Yes. People do quit without medication, and individual counseling, quitlines, and structured behavioral support can improve success. Evidence-based medicines can further increase the likelihood of sustained abstinence, especially for smokers who experience substantial withdrawal. A person who declines medication can still receive meaningful clinical support. CDC, 2024

Is quitting suddenly more effective than reducing cigarettes gradually?

Both immediate cessation and a planned route toward a smoke-free date can be accommodated in care. The clinically important elements are a credible cessation goal, support for withdrawal, and follow-up. Where a person cannot yet stop, treatment-assisted reduction may be part of preparation; reducing cigarette count alone does not equal eliminating combustible tobacco exposure. ATS, 2020

How long do nicotine cravings last?

Withdrawal symptoms are often most intense in the early days and weeks, while learned cue-related urges can recur for much longer. The duration varies across individuals. Medication, avoidance of predictable triggers, coping responses, and continued support can make these urges more manageable. CDC, Withdrawal Symptoms

Is nicotine replacement just substituting one addiction for another?

Medicinal NRT delivers nicotine without tobacco combustion, reducing exposure to many toxic constituents of cigarette smoke. Its controlled delivery and use as part of a cessation plan serve a different clinical function from continued cigarette smoking. Reducing combustible exposure is a major health gain even when a person needs a period of ongoing medicinal nicotine. FDA, 2026

Is vaping proven to help people stop smoking cigarettes?

The 2026 Cochrane living review found high-certainty evidence that nicotine e-cigarettes increase smoking abstinence compared with NRT in studied settings. That finding does not establish long-term safety or FDA approval as cessation medicine. Clinical decisions must also consider continuing vaping, product quality, age, pregnancy, and local regulation. Lindson et al., 2026

Can someone with depression or schizophrenia use smoking cessation medications?

Often, yes. Psychiatric conditions do not automatically exclude a person from evidence-based cessation treatment. Medication choice and monitoring should account for mood symptoms, suicidality, current prescriptions, adverse effects, and potential changes in psychotropic drug exposure when smoking stops. ATS, 2020

What if I already tried to quit several times?

Previous attempts provide actionable information about medication fit, withdrawal, triggers, access, and social conditions. Reassessment can lead to a different medication, combination NRT, more effective counseling, longer treatment when suitable, or better coordination of mental and physical health care. Re-engaging with treatment after a return to smoking is consistent with evidence-based cessation practice.

When is urgent medical care needed during a quit attempt?

Urgent assessment is appropriate for chest pain, serious breathing difficulty, fainting, severe confusion, new psychosis, or concerning medication reactions. Suicidal intent or an immediate danger requires emergency services. Coexisting alcohol or sedative withdrawal needs separate medical assessment because it may present life-threatening risks.

Related Articles

Nicotine Dependence and Tobacco Use Disorder: Diagnosis and Treatment — the related clinical classification, dependence, and diagnostic framework that complements this practical cessation guide.

Cluster Substance Use Disorders and Addiction Recovery — the parent scientific reference chapter, including the diagnosis, neurobiology, treatment, and recovery context for tobacco-related conditions.

Anxiety and Substance Use: Self-Medication, Withdrawal, and Comorbidity — psychological connections between anxiety, substance exposure, withdrawal, and coordinated care.

Neuroticism and Addiction: Substance Use, Negative Affect, and Risk — personality-related differences in negative affect and substance-related risk.

Addiction Treatment: Evidence-Based Options and How Care Works — comparative behavioral, medication, medical, and recovery-oriented approaches to addiction care.

What Is Addiction Recovery? Remission, Functioning, and Support — definitions of recovery, functioning, remission, and multiple recovery pathways.

References

American Thoracic Society. (2020). Leone, F. T., et al. Initiating pharmacologic treatment in tobacco-dependent adults: An official American Thoracic Society clinical practice guideline. American Journal of Respiratory and Critical Care Medicine, 202(2), e5–e31. https://doi.org/10.1164/rccm.202005-1982ST

Centers for Disease Control and Prevention. (2024). Benefits of quitting smoking. https://www.cdc.gov/tobacco/about/benefits-of-quitting.html

Centers for Disease Control and Prevention. (2024). How to quit smoking. https://www.cdc.gov/tobacco/about/how-to-quit.html

Centers for Disease Control and Prevention. (2025). Quit-smoking medicines are much safer than smoking. https://www.cdc.gov/tobacco/campaign/tips/quit-smoking/quit-smoking-medications/3-reasons-to-use-medicines-when-you-quit/quit-medicines-are-safer-than-smoking/index.html

Centers for Disease Control and Prevention. (n.d.). Seven common withdrawal symptoms. https://www.cdc.gov/tobacco/campaign/tips/quit-smoking/7-common-withdrawal-symptoms/index.html

Cochrane Tobacco Addiction Group. (2024). Interventions started during hospitalization to help people to stop smoking. https://www.cochrane.org/evidence/CD001837_interventions-started-during-hospitalisation-help-people-stop-smoking

DailyMed, U.S. National Library of Medicine. (2025). Bupropion hydrochloride (SR): Prescribing information. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8069c521-c49a-4b6d-baa8-4b0be897d585

Food and Drug Administration. (2026). E-cigarettes, vapes, and other electronic nicotine delivery systems (ENDS) authorized by the FDA. https://www.fda.gov/tobacco-products/market-and-distribute-tobacco-product/e-cigarettes-vapes-and-other-electronic-nicotine-delivery-systems-ends-authorized-fda

Food and Drug Administration. (2026). Nicotine is why tobacco products are addictive. https://www.fda.gov/tobacco-products/health-effects-tobacco-use/nicotine-why-tobacco-products-are-addictive

Lancaster, T., and Stead, L. F. (2017). Individual behavioural counselling for smoking cessation. Cochrane Database of Systematic Reviews, CD001292. https://doi.org/10.1002/14651858.CD001292.pub3

Lindson, N., Livingstone-Banks, J., Butler, A. R., et al. (2026). Electronic cigarettes for smoking cessation. Cochrane Database of Systematic Reviews, CD010216. https://doi.org/10.1002/14651858.CD010216.pub11

Livingstone-Banks, J., Fanshawe, T. R., Thomas, K. H., et al. (2023). Nicotine receptor partial agonists for smoking cessation. Cochrane Database of Systematic Reviews, CD006103. https://doi.org/10.1002/14651858.CD006103.pub9

Livingstone-Banks, J., Norris, E., Hartmann-Boyce, J., et al. (2019). Relapse prevention interventions for smoking cessation. Cochrane Database of Systematic Reviews, CD003999. https://doi.org/10.1002/14651858.CD003999.pub6

Stead, L. F., Koilpillai, P., Fanshawe, T. R., and Lancaster, T. (2016). Combined pharmacotherapy and behavioural interventions for smoking cessation. Cochrane Database of Systematic Reviews, CD008286. https://doi.org/10.1002/14651858.CD008286.pub3

Theodoulou, A., Chepkin, S. C., Ye, W., et al. (2023). Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation. Cochrane Database of Systematic Reviews, CD013308. https://doi.org/10.1002/14651858.CD013308.pub2

U.S. Preventive Services Task Force. (2021). Tobacco smoking cessation in adults, including pregnant persons: Interventions. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/tobacco-use-in-adults-and-pregnant-women-counseling-and-interventions

Whittaker, R., McRobbie, H., Bullen, C., et al. (2019). Mobile phone text messaging and app-based interventions for smoking cessation. Cochrane Database of Systematic Reviews, CD006611. https://doi.org/10.1002/14651858.CD006611.pub5

World Health Organization. (2024). WHO clinical treatment guideline for tobacco cessation in adults. Geneva: WHO. https://www.who.int/publications/i/item/9789240096431